Absent federal action, states take the lead on curbing drug costs
From the article:
Critics see these tailored efforts as falling short or potentially opening other loopholes. Requiring companies to report prices past a certain threshold, for example, might encourage them to consistently set prices just below that level. Maryland’s law is noteworthy because it includes a fine for drugmakers if price increases are deemed excessive — though a $10,000 fine is likely nominal for the billion-dollar industry, suggested Rachel Sachs, an associate law professor at Washington University, who researches drug regulations.
Read more here!fda health care finance health law policy pharmaceuticals rachel sachs regulation